Valuation: Polaryx Therapeutics, Inc.

Market Cap 97.2M 86.76M 80.64M 73.35M 138M 9.21B 140M 969M 379M 4.8B 365M 357M 15.37B P/E 2026 *
-10x
P/E 2027 * -6.78x
Enterprise Value 97.2M 86.76M 80.64M 73.35M 138M 9.21B 140M 969M 379M 4.8B 365M 357M 15.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day+3.59%
1 week+1.00%
Current month-2.42%
1 month-0.49%
3 months-12.55%
6 months-68.39%
1 week 1.88
Extreme 1.88
2.05
1 month 1.86
Extreme 1.8599
2.2
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 2023-02-28
Director of Finance/CFO 60 2024-05-31
Chief Tech/Sci/R&D Officer 56 2026-08-31
Director TitleAgeSince
Chairman 56 2021-05-31
Director/Board Member 60 2025-07-31
Director/Board Member - 2026-01-28
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Buy

Chief Executive Officer

88,453 0.1868%
2/18/26 Buy

Chief Financial Officer

2,867 -
1/29/26 Other

Chief Financial Officer

225,358 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.59%+1.00% - - 97.2M
+0.21%-4.63%+55.34%+71.32% 68.98B
-3.06%+0.93%+3.37%+56.43% 53.15B
-0.12%+5.10%+9.70%+41.14% 50.83B
-0.61%+4.07%+31.45%+35.92% 44.61B
-3.63%-4.04%+266.53%+433.68% 40.57B
-1.47%+3.69%+15.57%+111.30% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
-1.98%-8.77%-15.82%-8.78% 22.66B
Average -0.66%+1.15%+45.48%+87.16% 37.98B
Weighted average by Cap. -1.10%+2.33%+47.85%+92.42%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -8.18M -7.6M -6.92M -13.01M -868M -13.24M -91.32M -35.73M -453M -34.39M -33.66M -1.45B -16.42M -14.66M -13.63M -12.39M -23.32M -1.56B -23.74M -164M -64.04M -812M -61.64M -60.33M -2.6B
Net Debt - -
Projected Income Statement - Annual - Polaryx Therapeutics, Inc.
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
26-10-16 US$2.020 +3.59% 7,073
26-10-15 US$1.950 -1.02% 42,606
26-10-14 US$1.970 +1.55% 16,608
26-10-13 US$1.940 -3.48% 14,920
26-10-12 US$2.010 +0.50% 16,413
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Polaryx Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.950USD
Average target price
7.500USD
Spread / Average Target
+284.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Polaryx Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PLYX Stock